Lineage Cell (LCTX) Launches Its Latest Cell Therapy Program

On March 24, Lineage Cell Therapeutics Inc. (NYSE:LCTX) announced the motorboat of COR1, a caller preclinical compartment therapy programme targeting corneal endothelial disease. The institution is leveraging its proprietary AlloSCOPE level to make scalable off-the-shelf compartment therapies aimed astatine addressing the planetary shortage of donor corneal cells. Management highlighted the programme arsenic a earthy hold of its level and a measurement toward expanding its beingness successful ophthalmology portion supporting semipermanent growth. Commenting connected the update, CEO Brian Culley stated:

“We person elected to beforehand the COR1 programme into preclinical investigating and we besides judge the caller accomplishments reported with our AlloSCOPE “5D” manufacturing process could beryllium applied to this programme to further trim accumulation costs done large-scale production.”

Billion Photos/Shutterstock.com

Earlier connected March 6, Lineage Cell Therapeutics Inc. (NYSE:LCTX) reported 4th fourth gross of $6.6 cardinal compared to $2.9 cardinal past year. Chief Executive Officer Brian M. Culley stated that 2025 was a precise productive twelvemonth for the Lineage team. Culley emphasized that the company’s ngo is to pioneer the emerging tract of allogeneic compartment therapy extracurricular oncology by applying its proprietary compartment manufacturing exertion platform, AlloSCOPE, to the accumulation and transplantation of differentiated compartment types intended to regenerate cells a diligent has mislaid oregon mislaid relation of owed to assorted conditions.

Lineage Cell Therapeutics Inc. (NYSE:LCTX) is moving successful the US and internationally connected processing compartment replacement therapies for captious illnesses. Its portfolio includes OpRegen successful Phase 2a of objective trial, OPC1 successful Phase 1/2a multicenter objective trial, ReSonance (ANP1) and PNC1, some successful preclinical improvement stage, and is besides processing RND1.

While we admit the imaginable of LCTX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years.

Disclosure: None. Follow Insider Monkey connected Google News.